ACS chemical neuroscience molecule spotlight on telcagepant (MK-0974)

Corey R. Hopkins

doi:10.1021/cn200059f

ACS chemical neuroscience molecule spotlight on telcagepant (MK-0974)

Corey R. Hopkins

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.

Original language	English (US)
Pages (from-to)	334-335
Number of pages	2
Journal	ACS Chemical Neuroscience
Volume	2
Issue number	7
DOIs	https://doi.org/10.1021/cn200059f
State	Published - Jul 20 2011
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

Access to Document

10.1021/cn200059f

Cite this

@article{f3a27223a6b34e839481ff5fa24a923e,

title = "ACS chemical neuroscience molecule spotlight on telcagepant (MK-0974)",

abstract = "Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.",

author = "Hopkins, {Corey R.}",

year = "2011",

month = jul,

day = "20",

doi = "10.1021/cn200059f",

language = "English (US)",

volume = "2",

pages = "334--335",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "7",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on telcagepant (MK-0974)

AU - Hopkins, Corey R.

PY - 2011/7/20

Y1 - 2011/7/20

N2 - Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.

AB - Telcagepant (MK-0974) is a novel calcitonin gene-related peptide (CGRP) receptor antagonist currently undergoing clinical trials for migraine (http://www.merck.com/research/pipeline/home.html). MK-0974 is currently being studied in phase III clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=79960726863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960726863&partnerID=8YFLogxK

U2 - 10.1021/cn200059f

DO - 10.1021/cn200059f

M3 - Review article

C2 - 22816019

AN - SCOPUS:79960726863

VL - 2

SP - 334

EP - 335

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 7

ER -

ACS chemical neuroscience molecule spotlight on telcagepant (MK-0974)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this